The Texas Alzheimer’s Research and Care Consortium (TARCC) is a collaboration between seven of the state’s leading medical research institutions, working to improve early diagnosis, treatment, and prevention of Alzheimer’s disease.

Find out how you can become involved.

Alzheimer's Facts

brain-icon-small-11 in 9 people age 65+ has Alzheimer's disease.

brain-icon-small-1About 490,000 Texans are projected to have Alzheimer's by 2025.

brain-icon-small-11 in 3 seniors dies with Alzheimer's disease or another dementia.

brain-icon-small-1Every 66 seconds, someone in the United States develops Alzheimer’s.

Get Involved

TARCC Research Updates

TARCC investigators have been involved in a number of new, important research studies. Recently published research is wide ranging, spanning the gamut from clinical trials to new cognitive diagnostics; blood-based biomarkers in Mexican-Americans;  identification of additional risk genes; and validation of biomarker algorithms in AD patients and AD animal models.

View all TARCC researcher publications here.

Rachelle Doody, MD, PhD

Dr. Doody was lead author of a recent publication, "Blood-Based Biomarkers, Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer’s disease".  The findings add to the evidence of increased risk of AD associated with higher levels of Lp-PLA2 and homocysteine, and suggests that they work through different pathways. (Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 464-471.) 

Dr. Doody was lead author on behalf of the Alzheimer's Disease Study Group (ADCS) of a recent publication in the New England Journal of Medicine. The results of that study showed that Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability in two, phase-3 double blind clinical trials. (N Eng J Med 370:311-321, 2014).


Sid O'Bryant, PhD

Dr. O'Bryant published a study in the Journal of Alzheimer's Disease, looking at biomarkers of AD among Mexican Americans. This provocative study shows that the biomarker profile for AD among Mexican American cases is significantly different from that previously identified among non-Hispanic cases from many large scale studies. This is the first study to explicitly examine and provide support for blood-based biomarkers of AD among Mexican Americans. (J Alzheimers Dis 34:849-849, 2013).

Robert Barber, PhD

Dr. Barber was a co-author on a recent paper, looking at whether exploring the genetic basis of concentrations of putative blood biomarkers for AD could accelerate identification of additional risk genes using modest sample sizes. Four novel associations were observed between genetic variants and concentrations of AD biomarkers in the bloodstream. Genetic variants within the F7, ATP9B, MAP3K13 and ZNF320 genes were identified in the study. These genes have not been suggested previously as contributing to AD risk, despite multiple large-scale GWAS studies (PLoS One. 2015 Dec 1;10(12):e0142360. doi: 10.1371/journal.pone.0142360. eCollection 2015).

Donald R. Royall, MD

Dr. Royall was lead author on a recent publication in the Journals of Gerontology: "Series B: Psychological Science" (in press). TARCC investigators developed a method of diagnosing dementia from cognitive measures alone, and have validated it in the Hispanic Established Population for Epidemiological Studies in the Elderly (HEPESE). This research opens the door to studying dementia risks or outcomes in HEPESE and similar studies, even when participants cannot be seen by expert clinicians.

Dr. Royall, on behalf of TARCC, published a study in the Journal of Alzheimer's Disease where he described a new latent dementia proxy and validated it in several datasets, including well characterized subjects participating in the TARCC study. This type of analysis may make factor scores derived from latent variables a potentially attractive solution for dementia case-finding in rural or minority populations. (J Alzheimers Dis 37:89-97, 2013).